Novamind 5

[Jenifer Griffard]

Followingthe Transaction, the combined company will operate 13 wellness clinics and will be positioned as a leading psychedelic-assisted therapy provider in North America, leading its peer group in revenue with approximately C$10 million in annual pro-forma revenue based on the trailing four quarters.

"Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. The Novamind acquisition presents a transformational opportunity for Numinus to launch a strong U.S. platform through eight established, reputable, efficiently operating and revenue-producing clinics," says Payton Nyquvest, Founder and CEO, Numinus. "We prioritize working with the best partners in this industry and Novamind's U.S. market presence, complementary client programming and respected clinical research capabilities allow us to accelerate our strategic growth plans and broaden access to healing and wellness."

Mr. Nyquvest continued: "We expect this acquisition will significantly bolster our financial performance, growing Numinus' annual revenue to more than five times our current levels, and driving meaningful margin improvement through identified operating efficiencies. Our combined capabilities will deliver exceptional value for our clients, employees, and shareholders. We look forward to welcoming the Novamind team to the Numinus family."

Yaron Conforti, CEO and Co-Founder, Novamind, said, "This transaction offers significant value for Novamind's shareholders and provides compelling new opportunities for our employees, patients and research partners. The combination of Novamind's network of mental health clinics and research sites in the U.S. and Numinus' leadership in psychedelic-assisted psychotherapy in Canada creates a best-in-class company. The combined entity is supported with over C$50 million in pro-forma capital and positioned with distinct capabilities to serve a growing and diverse group of stakeholders. We are excited to join Numinus, a true leader in mental health innovation."

The combined company will operate 13 wellness clinics in focused geographies across the U.S. and Canada, and will continue developing and scaling innovative psychedelic therapy protocols and procedures for screening, preparation, dosing and integration targeting difficult-to-treat mental health conditions, including post-traumatic stress disorder (PTSD), COVID-19 burnout, depression, addiction and eating disorders. Operationally, the combined company will benefit from a centralized client care center for managing client inquiries, scheduling clients with appropriate providers, coordinating physician referral intakes, fulfilling prescription requests and facilitating insurance authorizations. The company's Utah clinics have secured approval for direct billing of intravenous (IV) ketamine for treatment-resistant depression from four major health insurance providers.

The combined company will operate four clinical research sites and a bioanalytical laboratory, all of which are currently supporting leading drug developers in psychedelic medicine with critical infrastructure and services. Select ongoing psychedelic medicine clinical trials include:

Completion of the Transaction is subject to a number of conditions including the receipt of regulatory, TSX and CSE approvals. Pursuant to TSX and CSE rules, the Transaction must also be approved by both Numinus' and Novamind's shareholders. Following anticipated shareholder approvals, the Transaction is expected to close in June 2022, at which point all Novamind operations will transition to Numinus branding.

Numinus will be convening a special meeting of its shareholders to consider the Transaction. Numinus currently anticipates that the special meeting will be held in early June 2022 and that an information circular containing additional details regarding the business of the special meeting will be mailed to shareholders in mid-May.

Novamind will be convening a special meeting of its shareholders to approve the Transaction. Novamind currently anticipates that the special meeting will be held in early June 2022 and that an information circular containing additional details regarding the business of the special meeting will be mailed to shareholders in mid-May.

The arrangement has been unanimously approved by the boards of directors of both Numinus and Novamind (with an interested director abstaining). Directors and officers of Novamind holding in aggregate 31% of the outstanding Novamind Shares, have entered into customary voting and support agreements to, amongst other things, vote in favour of the arrangement at the special meeting of Novamind shareholders to be held to consider the transaction.

Eight Capital is acting as financial advisor to Numinus' board of directors. The board of directors, based upon their investigations, concluded that the Transaction is in the best interests of Numinus shareholders, and will be recommending that shareholders vote in favour of a resolution at the special meeting of shareholders.

Clarus Securities has provided a fairness opinion to Novamind's board of directors (the "Novamind Board") and a special committee of independent directors of the Novamind Board (the "Novamind Special Committee") formed to, among other things, review and evaluate the terms of the Transaction and has provided its opinion that, as of the date of the opinion and subject to the assumptions and limitations contained in such opinion, Numinus' offered price is fair, from a financial point of view, to Novamind. The Novamind board of directors, based upon, among other things, their investigations and the recommendation of the Novamind Special Committee, including their consideration of that fairness opinion concluded that the Transaction is in the best interests of Novamind shareholders, and will be recommending that shareholders vote in favour of a resolution at its special meeting of shareholders.

Please ask to participate in Numinus' Q2 2022 Results Call. To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time. If prompted, please provide conference passcode 3547386.

Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Toronto, ON / 7. Oktober 2021 / Novamind Inc. (CSE: NM OTCQB: NVMDF FWB: HN2) ("Novamind" oder das "Unternehmen"), ein fhrendes Unternehmen fr psychische Gesundheit, das sich auf die Behandlung mit Psychedelika spezialisiert hat, freut sich, in seiner krzlich erffneten Klinik und Forschungseinrichtung in Murray, Utah, das Programm Psychedelic Palliative Care by Novamind (das "Palliativprogramm") zu starten.

Das Palliativprogramm ist eines der ersten seiner Art und kombiniert psychedelische Medizin mit Psychotherapie, Workshops, mehrtgigen Retreats und Gruppenuntersttzung fr Palliativpatienten und deren Familien, die mit einer chronischen schweren Krankheit zu kmpfen haben.

"Patienten, die palliativmedizinisch betreut werden, haben eine hhere Depressionsrate als die Allgemeinbevlkerung. Leider wirken Standardbehandlungen gegen Depressionen und Angstzustnde nicht bei jedem, knnen Nebenwirkungen verursachen und brauchen bis zu acht Wochen, um zu wirken", erklrte der Chief Scientific Officer (CSO) von Novamind, Dr. Paul Thielking. "Da psychedelische Arzneimittel im Allgemeinen nur geringe Nebenwirkungen haben und schnell wirken, sind sie vielversprechend fr Patienten, die krperlich krank sind und mglicherweise eine begrenzte Lebenserwartung haben."

Vor seiner Ttigkeit als CSO von Novamind entwickelte Dr. Thielking am Huntsman Cancer Institute (HCI) der University of Utah ketamingesttzte Behandlungsprotokolle fr Krebspatienten, die unter Depressionen leiden. Er leistete auch Pionierarbeit bei einer laufenden HCI-Studie, die die Durchfhrbarkeit einer gruppengesttzten Psychotherapie mit Psilocybin fr Krebspatienten mit Depressionen untersucht. Dr. Thielking leitet das multidisziplinre Team des Palliativprogramms, das sich aus Fachleuten fr psychische Gesundheit zusammensetzt, die auf Palliativmedizin und psychedelisch untersttzte Psychotherapie spezialisiert sind.

"Unser Gesundheitssystem tut sich schwer damit, den Millionen von Amerikanern zu helfen, die mit emotionalen, spirituellen und psychologischen Leiden im Zusammenhang mit chronischen oder schweren Krankheiten zu kmpfen haben", so Dr. Thielking. "Die psychedelische Palliativversorgung von Novamind ist darauf ausgerichtet, diesen Bedarf zu decken, indem sie schnell wirkende Medizin, innovative Behandlungsoptionen und therapeutisches Fachwissen in einer sicheren, frsorglichen Umgebung zusammenbringt."

Novamind ist ein Marktfhrer auf dem Gebiet der psychischen Gesundheit, der ber ein Netzwerk aus Kliniken und klinischen Forschungsstandorten einen sicheren Zugang zu psychedelischen Arzneimitteln ermglicht. Novamind ist ber sein Netzwerk von ,Cedar Psychiatry'-Kliniken Anbieter von ketamingesttzten Psychotherapien und anderen neuartigen Behandlungsmethoden. Das Unternehmen ist auerdem Betreiber von ,Cedar Clinical Research', einer Auftragsforschungsorganisation, die sich auf klinische Studien und evidenzbasierte Forschung fr die psychedelische Medizin spezialisiert hat. Sowohl ,Cedar Psychiatry' als auch ,Cedar Clinical Research' sind hundertprozentige Tochtergesellschaften von Novamind. Nhere Informationen darber, wie Novamind das geistige Wohlbefinden verbessert und Menschen whrend ihres gesamten Heilungsprozesses begleitet, finden Sie unter novamind.ca.

3a8082e126